In diabetic kidney disease, timing is everything. Traditionally, we wait for UACR and eGFR to signal trouble. But by then, valuable years have already passed, and kidney damage is often well underway.
We’ve shifted that timeline. With UPTM FTA screening, we can identify risk much earlier, before conventional markers even sound the alarm.
That earlier intervention window changes everything:
- It allows us to act before irreversible decline
- It gives patients more years of healthy kidney function
- It moves care from reactive to proactive
The visual tells the story clearly: a timeline where traditional care spots disease late, while UPTM FTA catches it at the earliest signs.
This is the essence of our hybrid model, which pairs advanced diagnostics with continuous support, allowing disease management to be about staying ahead rather than catching up. Because in conditions like diabetic kidney disease, the difference between “early” and “late” can be measured in years of life and quality of living.
